BibTex RIS Kaynak Göster

Yıl 2006, Cilt: 4 Sayı: 2, 13 - 20, 01.06.2006

Solmaz Çelebi

Öz

Kaynakça

  • 1. Lebel M, Tapiero B. Bacteremia, Sepsis and Septic Shock. In: Jenson HB, Baltimore RS (eds). Pediatric Infectious Diseases, 2nd edition. Philadelphia: WB Saunders Company; 2002. p.279-95.
  • 2. Butt W. Septic shock. Pediatr Clin North Am 2001; 48: 601-25.
  • 3. Bone RC. Pathophysiology of sepsis. Ann Intern Med 1991; 115: 457-69.
  • 4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55.
  • 5. Kaplan S. Bacteremia and septic shock. In: Long SL, Pickering LK, Prober GC (eds). Principles and Practice of Pediatric Infectious Disease, 2nd edition. New York, Churchill Livingstone; 2003.p.810-25.
  • 6. Sparrow A, Willis F. Management of septic shock in childhood. Emerg Med Austr 2004; 16: 125-34.
  • 7. Stormorken A, Powell KR. Sepsis and septic shock. In: Behrman RE, Kliegman RM, Jenson HB (eds). Nelson Text Book of Pediatrics 17th edition. Philadelphia, Saunders; 2004.p.846-50.
  • 8. Munford RS. Sepsis, severe sepsis and septic shock. In: Mandell GL, Bennet JE, Dolin R, (eds). Principles and Practice of Infectious Disease, 6th edition. Philadelphia, Curcill Livingstone; 2005.p.906-26.
  • 9. Dahmer MK, Randolph A, Vitalli S, Quasney MW. Genetic polymorphisms in sepsis. Crit Care Med 2005; 6: 61-73.
  • 10. Kellum JA, Angus DC. Genetic variation and risk of sepsis. Minerva Anestesiol 2003; 69:245-53.
  • 11. Goldstein B, Giroir B, Randolph A and the Members of the International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
  • 12. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345(19):1359-67.
  • 13. Casado-Flores J, Blanco-Quirós A, Asensio J, Arranz E, Garrote JA, Neiteo M. Serum procalcitonin in children with suspected sepsis: A comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med 2003; 4:190-5.
  • 14. Lopez AF, Cubells L, Garcia G, Pou F. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003; 22: 895-903.
  • 15. Gervaix A, Galetto-Lacour A, Gueron T, et al. Usefulness of procalcitonin and C-reactive protein rapid tests for the manangement of children with urinary tract infection. Pediatr Infect Dis 2001; 20: 507-11.
  • 16. Prat C, Dominguez J, Rodrigo C, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis 2003; 22: 438-42.
  • 17. Prat C, Dominguez J, Rodrigo C, et al. Procalcitonin, C-reactive protein and leukocyte counts in children with lower respiratory infection. Pediatr Infect Dis 2003; 22: 963-7.
  • 18. Doellner H, Arntzen KJ, Haereid PE, Aag S, Austgulen R. Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998; 132(2):295-9.
  • 19. Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M, Pacifico L. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49(1):60-8.
  • 20. Pershad J, Myners S, Ploumant C, Rosson C, Elam K, Wan J, Chin T. Bedside limited echocardiography the emergency physician is accurate during evaluation of critically ill patient. Pediatrics 2004; 114:667-71.
  • 21. Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-78.
  • 22. Ngo NT, Cao XT, Kneen R,et al: Acute management of dengue shock syndrome: A randomized double-blind comparison of 4 intravenous fluid regimens in the fist hour. Clin Infect Dis 2001; 32:204-13.
  • 23. Sparrow A, Hedderley, Nadel S. Choice of fluid resuscitation of septic shock. Emerg Med J 2002; 19:114-6.
  • 24. Wills B, Dung NM, Loan HaT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877-89.
  • 25. Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support in fluid-refractory septic shock. Pediatrics 1998; 102:19.
  • 26. Tabbutt S. Heart failure in pediatric septic septic shock: Utilizing inotropic support. Crit Care Med 2001; 29:231-6.
  • 27. Matok I, Vard A, Efrati O, Rubinshtein M, Vishne T, Leibovitch L, Adam M, Barzliay Z, Paret G. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 2005; 23:305-10.
  • 28. Holmes CL, Walley KR. Vasopressin in the ICU. Curr Opin Critical Care 2004; 10:442-8
  • 29. Pizarro CF, Eduardo JT, Damiani D, Carcill JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med 2005; 33: 855-9.
  • 30. Maar SP. Emergency care in pediatric septic shock. Pediatric Emergency Care 2004; 20: 617-24.
  • 31. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
  • 32. Cariou A, Vinsonneau C, Dhainaut JF. Adjunctive therapies in sepsis: An evidence based review. Crit Care Med 2004; 32: 562-70.
  • 33. American Academy of Pediatrics, American Heart Association. Fulid therapy and medications for shock and cardiak arrest. PALS provider manual 2002:127-53.
  • 34. Briassoulis G, Zavras N, Hatzis T. Malnutrition, nutritional indices, and early enteral feeding in critically ill children. Nutrition 2001;17:548-57.
  • 35. Kirch EA, Giroir BP. Improving the outcome of septic shock in children. Curr Opin Infect Dis 2000; 13:253-8.
  • 36. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24(9):1431-40.
  • 37. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334 (26):1697-702.
  • 38. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271(23):1836-43.
  • 39. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121(1):1-5.
  • 40. Parker MM, Hazelzet JA, Carcillo JA. Pediatric considerations. Crit Care Med 2004; 32: 591-4.

Çocuklarda Sepsis ve Septik Şok

Yıl 2006, Cilt: 4 Sayı: 2, 13 - 20, 01.06.2006

Solmaz Çelebi

Öz

Sepsis yıllar boyunca tedavi açısından ciddi problemler oluşturan ve yüksek mortaliteye neden olan bir sorundur. Mortalite oranı 1960'larda %100 iken, günümüzde erken tanı ve tedavi ile mortalite oranı azalmıştır. Ancak halen çocuklarda ölüm nedenleri arasında ilk on neden içindedir 1 .

Kaynakça

  • 1. Lebel M, Tapiero B. Bacteremia, Sepsis and Septic Shock. In: Jenson HB, Baltimore RS (eds). Pediatric Infectious Diseases, 2nd edition. Philadelphia: WB Saunders Company; 2002. p.279-95.
  • 2. Butt W. Septic shock. Pediatr Clin North Am 2001; 48: 601-25.
  • 3. Bone RC. Pathophysiology of sepsis. Ann Intern Med 1991; 115: 457-69.
  • 4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55.
  • 5. Kaplan S. Bacteremia and septic shock. In: Long SL, Pickering LK, Prober GC (eds). Principles and Practice of Pediatric Infectious Disease, 2nd edition. New York, Churchill Livingstone; 2003.p.810-25.
  • 6. Sparrow A, Willis F. Management of septic shock in childhood. Emerg Med Austr 2004; 16: 125-34.
  • 7. Stormorken A, Powell KR. Sepsis and septic shock. In: Behrman RE, Kliegman RM, Jenson HB (eds). Nelson Text Book of Pediatrics 17th edition. Philadelphia, Saunders; 2004.p.846-50.
  • 8. Munford RS. Sepsis, severe sepsis and septic shock. In: Mandell GL, Bennet JE, Dolin R, (eds). Principles and Practice of Infectious Disease, 6th edition. Philadelphia, Curcill Livingstone; 2005.p.906-26.
  • 9. Dahmer MK, Randolph A, Vitalli S, Quasney MW. Genetic polymorphisms in sepsis. Crit Care Med 2005; 6: 61-73.
  • 10. Kellum JA, Angus DC. Genetic variation and risk of sepsis. Minerva Anestesiol 2003; 69:245-53.
  • 11. Goldstein B, Giroir B, Randolph A and the Members of the International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
  • 12. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345(19):1359-67.
  • 13. Casado-Flores J, Blanco-Quirós A, Asensio J, Arranz E, Garrote JA, Neiteo M. Serum procalcitonin in children with suspected sepsis: A comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med 2003; 4:190-5.
  • 14. Lopez AF, Cubells L, Garcia G, Pou F. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003; 22: 895-903.
  • 15. Gervaix A, Galetto-Lacour A, Gueron T, et al. Usefulness of procalcitonin and C-reactive protein rapid tests for the manangement of children with urinary tract infection. Pediatr Infect Dis 2001; 20: 507-11.
  • 16. Prat C, Dominguez J, Rodrigo C, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis 2003; 22: 438-42.
  • 17. Prat C, Dominguez J, Rodrigo C, et al. Procalcitonin, C-reactive protein and leukocyte counts in children with lower respiratory infection. Pediatr Infect Dis 2003; 22: 963-7.
  • 18. Doellner H, Arntzen KJ, Haereid PE, Aag S, Austgulen R. Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998; 132(2):295-9.
  • 19. Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M, Pacifico L. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49(1):60-8.
  • 20. Pershad J, Myners S, Ploumant C, Rosson C, Elam K, Wan J, Chin T. Bedside limited echocardiography the emergency physician is accurate during evaluation of critically ill patient. Pediatrics 2004; 114:667-71.
  • 21. Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-78.
  • 22. Ngo NT, Cao XT, Kneen R,et al: Acute management of dengue shock syndrome: A randomized double-blind comparison of 4 intravenous fluid regimens in the fist hour. Clin Infect Dis 2001; 32:204-13.
  • 23. Sparrow A, Hedderley, Nadel S. Choice of fluid resuscitation of septic shock. Emerg Med J 2002; 19:114-6.
  • 24. Wills B, Dung NM, Loan HaT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877-89.
  • 25. Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support in fluid-refractory septic shock. Pediatrics 1998; 102:19.
  • 26. Tabbutt S. Heart failure in pediatric septic septic shock: Utilizing inotropic support. Crit Care Med 2001; 29:231-6.
  • 27. Matok I, Vard A, Efrati O, Rubinshtein M, Vishne T, Leibovitch L, Adam M, Barzliay Z, Paret G. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 2005; 23:305-10.
  • 28. Holmes CL, Walley KR. Vasopressin in the ICU. Curr Opin Critical Care 2004; 10:442-8
  • 29. Pizarro CF, Eduardo JT, Damiani D, Carcill JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med 2005; 33: 855-9.
  • 30. Maar SP. Emergency care in pediatric septic shock. Pediatric Emergency Care 2004; 20: 617-24.
  • 31. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
  • 32. Cariou A, Vinsonneau C, Dhainaut JF. Adjunctive therapies in sepsis: An evidence based review. Crit Care Med 2004; 32: 562-70.
  • 33. American Academy of Pediatrics, American Heart Association. Fulid therapy and medications for shock and cardiak arrest. PALS provider manual 2002:127-53.
  • 34. Briassoulis G, Zavras N, Hatzis T. Malnutrition, nutritional indices, and early enteral feeding in critically ill children. Nutrition 2001;17:548-57.
  • 35. Kirch EA, Giroir BP. Improving the outcome of septic shock in children. Curr Opin Infect Dis 2000; 13:253-8.
  • 36. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24(9):1431-40.
  • 37. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334 (26):1697-702.
  • 38. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271(23):1836-43.
  • 39. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121(1):1-5.
  • 40. Parker MM, Hazelzet JA, Carcillo JA. Pediatric considerations. Crit Care Med 2004; 32: 591-4.
Toplam 40 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Solmaz Çelebi

Yayımlanma Tarihi 1 Haziran 2006
Yayımlandığı Sayı Yıl 2006 Cilt: 4 Sayı: 2

Kaynak Göster

APA Çelebi, S. (2006). Çocuklarda Sepsis ve Septik Şok. Güncel Pediatri, 4(2), 13-20.
AMA Çelebi S. Çocuklarda Sepsis ve Septik Şok. Güncel Pediatri. Haziran 2006;4(2):13-20.
Chicago Çelebi, Solmaz. “Çocuklarda Sepsis ve Septik Şok”. Güncel Pediatri 4, sy. 2 (Haziran 2006): 13-20.
EndNote Çelebi S (01 Haziran 2006) Çocuklarda Sepsis ve Septik Şok. Güncel Pediatri 4 2 13–20.
IEEE S. Çelebi, “Çocuklarda Sepsis ve Septik Şok”, Güncel Pediatri, c. 4, sy. 2, ss. 13–20, 2006.
ISNAD Çelebi, Solmaz. “Çocuklarda Sepsis ve Septik Şok”. Güncel Pediatri 4/2 (Haziran2006), 13-20.
JAMA Çelebi S. Çocuklarda Sepsis ve Septik Şok. Güncel Pediatri. 2006;4:13–20.
MLA Çelebi, Solmaz. “Çocuklarda Sepsis ve Septik Şok”. Güncel Pediatri, c. 4, sy. 2, 2006, ss. 13-20.
Vancouver Çelebi S. Çocuklarda Sepsis ve Septik Şok. Güncel Pediatri. 2006;4(2):13-20.